《Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as firstline and nonfirstline treatments for the patients of colorectal cancers with unresectable hepatic metastases》.pdfVIP

Chinese-German J Clin Oncol May 2014, Vol. 13, No. 5, P229–P234 DOI 10.1007/s10330-014-1297-0 Efficacy comparison between hepatic arterial infusion chemotherapy plus systemic chemotherapy used as first-line and non-first-line treatments for the patients of colorectal cancers with unresectable hepatic metastases* Ping Chen1, 2, 3, Bei Zhang1, 2, 3, Guifang Guo1, 2, 3, Liangping Xia1, 2, 3, Huijuan Qiu1, 2, 3 1 State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China 2 VIP Region, Sun Yat-sen University Cancer Center, Guangzhou 510060, China 3 Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China Received: 19 February 2014 / Revised: 6 March 2014 / Accepted: 15 April 2014 © Huazhong University of Science and Technology 2014 Abstract Objective: The combination of hepatic arterial chemotherapy (HA IC) and systemic chemotherapy (SYC) has potential effect on colorectal cancer (CRC) patients with unresectable hepatic metastasis. The aim of this retrospective study was to investigate the efficacy and safety of this combined therapeutic regimen on Chinese patients based on single institute experiences. Methods: All 54 patients of this retrospective analysis were diagnosed with CRC with unresectable liver metas- tasis and received combined HA IC and SYC. Among the patients, 23 of them received HA IC plus SYC when they developed liver metastases as first-line treatment (Group 1), and 31 patients received HA IC plus SYC as non-first-line treatment (Group 2). The different efficacy in two groups was analyzed by SPSS 19.0. Results: The overall response rate (ORR) were 52.2% and 25.8% respectively in Groups 1 and 2 (P = 0.047), and the disease control rate (DCR) were 65.2%